Figure 1.

iCM Pharmacodynamic Response to DOX

(A) Workflow for generating patient-specific iCMs; (B) summary pharmacodynamic data report mean viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolim bromide from patient-specific iCMs, in triplicate (n = 9); and (C) iCM pharmacodynamics by annexin-PI for 24-hour DOX exposure highlight a significant increase in apoptosis between 24 and 48 hours (n = 3). iCM = induced cardiomyocyte; iPSC = induced pluripotent stem cell; PBMC = peripheral blood mononuclear cell.